| Capital Markets Industry | Financials Sector | - CEO | LSE Exchange | GG00B8P59C08 ISIN |
| United Kingdom Country | 1,050 Employees | - Last Dividend | - Last Split | - IPO Date |
Syncona Limited operates as a specialized fund with a primary focus on investments across multiple asset classes including hedge, equity, and long-term alternative investment funds. It harnesses a strategic approach to manage a diverse portfolio comprising private equity, debt, fixed income, and alternative investments, targeting sectors with high growth potential. The fund uniquely positions itself by emphasizing investments in the healthcare and life sciences sector, particularly in fields such as Cell therapy, gene therapy, biologics, and small molecules. Syncona's investment strategy is global, engaging in the public equity and fixed income markets worldwide. The firm is dedicated to generating attractive medium to long-term returns by channeling investments into leading long-only and alternative investment funds, managed by proven managers across multiple asset classes. Additionally, it allocates resources into separately managed account portfolios, further diversifying its investment approach to optimize returns for investors.
Syncona Limited offers a wide range of investment products and services focused primarily on generating value through diversified asset management. These include: